• Indonesia is a large population country with over 260 million people. It is a very potential market for health products.

• The National Health Insurance Program (JKN/BPJS) has covered 175 million members which is 66% of the total population. BPJS has made a bigger target which means there will be more Indonesians have access to health service. This condition contributes to the growth of drug consumption and encourages the development of the pharmaceutical industry as a whole which is predicted to grow 5-6% to 78 trillion through new products and innovation.

• During 2018, the pharmaceutical, chemical and traditional medicine industry has grown by 4.46% which contributes 2.78% of GDP from the non-oil & gas processing industry.

• The pharmaceutical industry and raw materials are one of the priority industries in the national industrial development policy which have been developed through various incentives, which one of them is by tax-reducing and import duties borne by the government.

• The current situation is that the pharmaceutical industry in Indonesia is only able to meet 75% of domestic drug needs and the raw materials are still 90% imported. The current situation is that the pharmaceutical industry in Indonesia is only able to meet 75% of domestic drug needs and 90% of raw materials are still imported. It is an opportunity that must be exploited by domestic industry players to increase the domestic content of each product.

• Currently, there is a trend of increased consumption of health products by the public. This trend has the potential to grow and develop into new or normal conditions. Under this condition, the public will make pharmaceutical spending as a priority.